# ALX Oncology Holdings Inc: overview ALXO · Nasdaq · CIK 1810182 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/alxo.md) · [Financials](/companies/alxo/financials.md) · [Filings](/companies/alxo/filings.md) · [Insiders](/companies/alxo/insiders.md) Latest reported revenue: [$0](/filings/0000950170-23-007013.md) for Q4 FY2020, three months to 2020-12-31, from the 10-K filed Mar 9, 2023 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000950170-23-007013). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.58)](/filings/0001193125-25-272281.md) | not reported | [(0.58)](/filings/0001193125-26-213399.md) | [(0.49)](/filings/0001193125-26-337920.md) | [(0.41)](/filings/0001193125-25-272281.md) | not reported | [(0.17)](/filings/0001193125-26-213399.md) | [(0.13)](/filings/0001193125-26-337920.md) | | Free cash flow | $m | [(25.5) d](/filings/0001193125-25-272281.md) | [(32.1) d](/filings/0001193125-26-098454.md) | [(24.7)](/filings/0001193125-26-213399.md) | [(23.5) d](/filings/0001193125-26-337920.md) | [(17.1) d](/filings/0001193125-25-272281.md) | [(19.0) d](/filings/0001193125-26-098454.md) | [(18.7)](/filings/0001193125-26-213399.md) | [(16.1) d](/filings/0001193125-26-337920.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0000950170-23-007013.md) | [0.0](/filings/0000950170-23-007013.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.07)](/filings/0000950170-24-027955.md) | [(3.03)](/filings/0000950170-25-034761.md) | [(3.74)](/filings/0001193125-26-098454.md) | [(2.58)](/filings/0001193125-26-098454.md) | [(1.90)](/filings/0001193125-26-098454.md) | | Free cash flow | $m | [(68.8)](/filings/0000950170-24-027955.md) | [(90.7)](/filings/0000950170-25-034761.md) | [(132)](/filings/0001193125-26-098454.md) | [(122)](/filings/0001193125-26-098454.md) | [(84.4)](/filings/0001193125-26-098454.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/alxo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $26.9m | 13,011,849 | | Unchanged | | [venBio Partners LLC](/funds/1776382.md) | 2026-06-30 | $26.7m | 12,884,638 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.3m | 7,399,530 | | Added +6,951,731 | | [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $15.3m | 7,392,504 | | Reduced −571,684 | | [Blackstone Inc.](/funds/1393818.md) | 2026-06-30 | $13.6m | 6,593,543 | | Added +766,999 | | [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $12.5m | 6,025,240 | | Added +290,620 | | [SILVERARC CAPITAL MANAGEMENT, LLC](/funds/1816307.md) | 2026-06-30 | $11.9m | 5,744,757 | | New +5,744,757 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $11.7m | 5,655,487 | | Reduced −7,356,362 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.3m | 4,973,436 | | Added +793,700 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $6.6m | 3,184,713 | | Unchanged | ## Recent filings [All 420 filings](/companies/alxo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 01:21 ET | [SCHEDULE 13D/A](/filings/0000905148-26-004485.md) | Ownership report, active investor, amended | 0000905148-26-004485 | | 2026-10-15 | 20:55 ET | [8-K](/filings/0001193125-26-422992.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-422992 | | 2026-08-06 | 20:01 ET | [10-Q](/filings/0001193125-26-337920.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337920 | | 2026-08-06 | 12:05 ET | [8-K](/filings/0001193125-26-336843.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336843 | | 2026-06-30 | 20:01 ET | [8-K](/filings/0001193125-26-290447.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-290447 | | 2026-06-26 | 20:02 ET | [8-K](/filings/0001193125-26-285425.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-285425 | | 2026-06-11 | 20:02 ET | [8-K](/filings/0001193125-26-267472.md) | 5.07 Shareholder vote results | 0001193125-26-267472 | | 2026-05-27 | 20:17 ET | [SCHEDULE 13D/A](/filings/0001643828-26-000002.md) | Ownership report, active investor, amended | 0001643828-26-000002 | | 2026-05-08 | 12:11 ET | [10-Q](/filings/0001193125-26-213399.md) | Quarterly report, period 2026-03-31 | 0001193125-26-213399 | | 2026-05-08 | 12:06 ET | [8-K](/filings/0001193125-26-213380.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-213380 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-098454.md), filed Mar 9, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1810182 - Tickers: ALXO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.